Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1



Status:Recruiting
Conditions:Breast Cancer, Skin Cancer, Cervical Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Brain Cancer, Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 85
Updated:3/14/2019
Start Date:February 2015
End Date:June 2020
Contact:Oana C. Danciu, M.D.
Email:ocdanciu@uic.edu
Phone:312-996-1581

Use our guide to learn which trials are right for you!

(STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1

This Phase I dose escalation study will evaluate Procaspase Activating Compound-1 (PAC-1), a
small molecule that activates procaspase -3 to caspase-3, resulting in apoptosis of cancer
cells, in patients with advanced malignancies. As of March 1, 2019, only patients with
neuroendocrine tumors will be enrolled in Component 1 of this study. PAC-1 is taken orally on
days 1-21 of a 28-day cycle. The maximum tolerated dose (MTD) of PAC-1 (5 dose levels) will
be determined using a modified-Fibonacci dose-escalation 3+3 design. Treatment continues
until disease progression, unacceptable toxicity, physician discretion, or patient refusal.


Inclusion Criteria:

1. Male or female ≥ 18 years of age

2. Diagnosis of advanced solid tumor or hematologic malignancy (limited to lymphoma) that
has failed or become intolerant to standard therapy

3. Has measurable disease, defined as at least 1 tumor that fulfills the criteria for a
target lesion according to RECIST 1.1, or lymphoma that fulfills the Deauville PET
Criteria

4. Has an ECOG PS of 0, 1, or 2

5. Has total bilirubin < 1.5 mg/dL, serum albumin > 3.0 gm/dL, AST and ALT < 1.5 ULN or <
3 x ULN for subjects with known hepatic metastases

6. Has serum creatinine < 1.5 × ULN

7. Has hemoglobin ≥ 10 g/dL, ANC ≥ 1.5 × 109/L, and platelet count ≥ 100 × 109/L

8. Must be able to take oral medication and to maintain a fast as required for 2 hours
before and 1 hour after capsule(s) administration

9. Must be willing and able to comply with study

10. Has read, understood, and signed the ICF

11. Women of childbearing potential must not be pregnant or breast-feeding. In addition, a
medically acceptable method of birth control must be used or total abstinence. Women
who are postmenopausal for at least 1 year or surgically sterile (bilateral tubal
ligation, bilateral oophorectomy, or hysterectomy) are not considered to be WOCP

12. Men who are not surgically or medically sterile must agree to use an acceptable method
of contraception. Male patients with female sexual partners who are pregnant, possibly
pregnant, or who could become pregnant during the study must agree to use condoms at
least one month after the last dose of study drug. Total abstinence for the same study
period is an acceptable alternative

13. Prior systemic treatments for metastatic disease are permitted but may not be ongoing,
including targeted therapies, biologic response modifiers, chemotherapy, hormonal
therapy, or investigational therapy

14. Willingness to donate blood for biomarker studies related to the type of therapies
used in this trial and the tumor types being treated

Exclusion Criteria:

1. Had surgery within 4 weeks prior to study treatment except for minor procedures
(hepatic biliary stent placement is allowed)

2. Gliomas are excluded, as well as any history of brain metastases, seizures or
underlying brain injury

3. May not have received cytotoxic chemotherapy, targeted therapies, biologic response
modifiers, chemotherapy, and hormonal therapy within the last 3 weeks, or nitrosureas
within the last 6 weeks prior to study treatment.

4. Has a history of blood clots, pulmonary embolism, or DVT unless controlled by
anticoagulant treatment

5. Has a history of an arterial thromboembolic event within the prior six months
including CVA, TIA, MI, or unstable angina

6. Has uncontrolled HIV or hepatitis B or C

7. Has any clinically significant infection

8. Has any other severe, uncontrolled medical condition, including uncontrolled DM or
unstable CHF

9. Radiation therapy to more than 25% of the bone marrow

10. Prior allogeneic bone marrow or organ transplantation

11. > Grade 1 peripheral neuropathy within 14 days before enrollment.

12. Patient has received other investigational drugs with 14 days before enrollment

13. Other severe acute or chronic medical or psychiatric conditions or laboratory
abnormality that may increase the risk associated with study participation

14. Abnormalities on 12-lead electrocardiogram (ECG) considered by the investigator to be
clinically significant (such as acute ischemia, left bundle branch block, ventricular
arrhythmias) or baseline prolongation of the rate-corrected QT interval (e.g.,
repeated demonstration of QTc interval > 480 milliseconds)

15. Presence of any non-healing wound, fracture, or ulcer

16. Has any condition that, in the opinion of the investigator, might jeopardize the
safety of the patient or interfere with protocol compliance

17. Has any mental or medical condition that prevents the patient from giving informed
consent
We found this trial at
3
sites
Baltimore, Maryland 21287
Phone: 410-955-8804
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
2035 W Taylor St
Chicago, Illinois
(312) 996-4350
Phone: 312-996-1581
University of Illinois at Chicago A major research university in the heart of one of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
640 Jackson Street
Saint Paul, Minnesota 55101
651-254-3456
Principal Investigator: Richard Peterson, MD
Phone: 651-254-3572
Regions Hospital Established in 1872, Regions Hospital is a private, not-for-profit organization. The hospital provides...
?
mi
from
Saint Paul, MN
Click here to add this to my saved trials